The White House denies a report that President Donald Trump applied for “compassionate use” access to a weight loss drug. Multiple outlets report the claim centers on retatrutide, a drug that is not approved for general use in the United States. According to the reports, an unnamed 79-year-old man was said to have received special access through a compassionate-use program, raising questions about whether the same type of access was connected to Trump. The White House responds by criticizing the report and disputing the suggestion that Trump applied for the program or sought the drug through it. The dispute is presented as a factual challenge to the reporting, rather than an endorsement or confirmation of any request. The outlets also note that retatrutide’s status remains a key element of the controversy because it is described as unapproved in the context of the compassionate-use program. The White House’s position is that the claim about Trump’s involvement is not accurate.